Brand name: ALIGIRITINIB
Composition:
Each tablet contains:
Gilteritinib Fumarate………………………..40mg
Indications:
This product is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.
Dosage:
- Three tablets (120mg) once a day.
- Take with water, with or without food, swallow tablets whole do not break or crush.
- In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended.
Contraindications:
- Patients who are allergic to this product.
Warnings:
- Posterior reversible encephalopathy syndrome (PRES): Discontinue in patients who develop PRES.
- Prolonged QT Interval: Interrupt and reduce dosage in patients who have a QTc >500 msec. Correct hypokalemia or hypomagnesemia prior to and during administration.
- Pancreatitis: Interrupt and reduce the dose in patients who develop pancreatitis.
- Embryo-Fetal Toxicity: can cause fetal harm when administered to a pregnant woman. Do not breastfeed within two months of the last dose.
Adverse Effects:
Differentiation syndrome, thrombocytopenia, neutropenia, anemia, dizziness, headache, cough, nausea, taste disorders, prolonged QT interval.
Dosage form: Yellow tablets.
Expiry date: 48 months from the date of manufacture.
Packaging:
- 90 tablets/ bottle.
Storage:
- Protected from light, sealed in original packaging, and stored at 20℃- 25℃.
- Keep out of reach of children.
DISCLAIMER
The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.
For your safety:
Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.
